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Since it has been widely recognised that renal cell carcinoma is refractory to standard therapies such as chemotherapy and
radiotherapy, a new modality of treatment is needed. One of the potential alternative therapies for renal cell carcinoma may
be inhibition of angiogenesis. In this study, we analysed the inhibitory effects of several potential agents on expression of
angiogenic factors such as vascular endothelial growth factor and basic ﬁbroblast growth factor, which are the main mediators
in angiogenesis of renal cell carcinoma. We used medroxyprogesterone acetate, interferon-alpha, interferon-gamma,
minocycline hydrochrolide and genistein, which are known to be antiangiogeneic. Northern blot analyses revealed that, among
the ﬁve agents examined, genistein had a strong inhibitory effect on expression of vascular endothelial growth factor mRNA
and basic ﬁbroblast growth factor mRNA. Medroxyprogesterone acetate and interferon-alpha did not signiﬁcantly decrease
the level of either vascular endothelial growth factor mRNA or basic ﬁbroblast growth factor mRNA. Interferon-gamma and
minocycline had mild inhibitory effects on vascular endothelial growth factor mRNA and basic ﬁbroblast growth factor mRNA
expression. Genistein also inhibited both vascular endothelial growth factor mRNA and basic ﬁbroblast growth factor mRNA
expression after treatment with epidermal growth factor and hypoxia. These ﬁndings suggest that one of the mechanisms of
the inhibition of angiogenesis by genistein is suppression of the expression of the angiogenic factors vascular endothelial
growth factor and basic ﬁbroblast growth factor in renal cell carcinoma.
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At present there are no standard effective therapies but surgery for
patients with renal cell carcinoma (RCC). RCC is resistant to
chemotherapy, radiotherapy and other systemic therapies. Only a
minority of patients with RCC can beneﬁt from immunotherapy
with interferon (IFN) or interleukin-2. These facts make it frustrat-
ing for urologists and oncologists to treat RCC patients. Therefore,
a new modality of treatment for patients with RCC is needed.
Angiogenesis is essential for the growth, progression and metas-
tasis of solid tumours (Liota et al, 1991; Weidner et al, 1991;
Folkman, 1996). Most RCCs are characterized by hypervascularity.
We have demonstrated that vascular endothelial growth factor
(VEGF) and basic ﬁbroblast growth factor (bFGF) play important
roles in eliciting angiogenesis in RCC (Takahashi et al, 1994). In
addition, we have reported that overexpression of VEGF receptors,
VEGFR-1 (FLT-1) and VEGFR-2 (KDR), is observed in parallel
with that of VEGF in RCC (Takahashi et al, 1999). These ﬁndings
indicate that the VEGF–VEGF receptor pathway is important for
angiogenesis in RCC as well as other cancers (Claffey and Robin-
son, 1996). Therefore, abrogating this pathway can lead to
inhibition of tumour growth via suppression of angiogenesis.
Indeed, several studies have shown reduction of tumour growth
by disrupting this pathway in various tumours. Those disruptions
were caused by a neutralizing antibody, receptor antagonist, anti-
sense constructs, or inhibitor of receptor tyrosine-kinases (Kim et
al, 1993; Claffey et al, 1996; Drevs et al, 2000).
Several reports have demonstrated that interferon-alpha (IFN-a)
and interferon-beta (IFN-b) can down-regulate the expression and
production of bFGF, leading to inhibition of angiogenesis in various
human cancers (Singh et al, 1995; Dinney et al, 1998). This observa-
tion prompted us to investigate whether there are agents that
regulate expression of VEGF as well as bFGF. In this study, we
examined the effects of medroxyprogesterone acetate (MPA), IFN-
a, interferon-gamma (IFN-g), minocycline, and genistein. MPA,
IFN-a and IFN-g are clinically administrated against RCC patients
and are known to have antiangiogenic effects (Sipos et al, 1994;
Pepper et al, 1996). However, previous studies have shown that
these agents produce low response rates in RCC patients. Therefore,
we hypothesised that these results would be reasonable if they did
not inhibit the expression of VEGF and bFGF in RCC cell lines.
We chose these agents to clarify this issue.
Our previous study showed that minocycline inhibits experimental
metastasis of mouse renal adenocarcinoma (Masumori et al, 1994).
In addition, minocycline inhibits angiogenesis in vivo and in vitro
(Tamargo et al, 1991; Gilbertson-Beadling et al, 1995). These results
stimulated us to study whether minocycline could inhibit angiogensis
by suppressing VEGF and bFGF expression in RCC. If this drug has
such an effect, this could be a novel therapeutic agent.
Genistein, an isoﬂavone in soybeans, is also antiangiogenic (Fotsis
et al, 1995). Additionally, genistein inhibits hypoxia-induced VEGF
overexpression by suppressing c-src activity (Mukhopadhyay et al,
1995). However, it remains unclear whether this inhibits angiogen-
esis by regulating the expression of angiogenic factors in RCC.
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www.bjcancer.comHere we report that, among the agents tested, genistein has a
strong inhibitory effect on expression of VEGF and bFGF in
RCC cell lines in vitro.
MATERIALS AND METHODS
Cell lines and cultures
Human renal cell carcinoma cell lines SMKT-R-1 and SMKT-R-3,
which were established in our laboratory, were maintained in mini-
mal essential medium with D-valine modiﬁcation medium
containing 10% FBS (Miyao et al, 1989). Hypoxia was induced
by using a BBL GasPak Pouch (Becton Dickinson, Cockeysville,
MD, USA), which catalytically reduces O2 to an undetectable level.
Reagents
Epidermal growth factor was purchased from Sigma Chemical Co.
(St. Louis, MO, USA). MPA and genistein were from Waco Pure
Chemical Industries (Osaka, Japan). Human IFN-a-2b and mino-
cycline were obtained from Schering Plough (Osaka, Japan) and
Lederle Ltd. (Tokyo, Japan), respectively. Human IFN-g was gener-
ously provided by Shionogi and Co., Ltd. (Osaka, Japan).
RNA extraction
Total RNA was obtained from the cell lines using a TRIzol kit
(Gibco BRL, Grand Island, NY, USA) according to the procedure
recommended by the supplier.
Northern blot analysis
Twenty micrograms of total RNA was electrophoresed in 1% agar-
ose gels containing formaldehyde and transferred to a NitroPlus
membrane (Micron Separation, Inc, Westboro, MA, USA). Hybri-
disation and washing were performed as described previously
(Takahashi et al, 1994). Brieﬂy, hybridisation was carried out in
50% formamide, 56 SCC, 56 Denhart’s solution, 5 mM EDTA,
0.1% SDS, 10% dextran sulphate and 100 mgm l
71 denatured
salmon sperm DNA at 428C for 14–16 h. The ﬁlters were washed
twice with 0.16 SCC and 0.1% SDS at room temperature for
10 min each and then washed twice at 658C for 30 min each. All
DNA probes were labelled with a-
32P-dCTP (Amersham, Tokyo,
Japan) using a random primer labelling system (Boehringer–
Mannheim, Mannheim, Germany). After hybridisation, all blots
were exposed to Kodak XAR ﬁlm with an intensifying screen at
7808C. The hybridised probes for VEGF, bFGF and b-actin, were
described in a previous report (Takahashi et al, 1994). The level of
expression of each gene was determined using a Bio-Image-Analy-
zer (BAS2000; Fujix, Kanagawa, Japan). The percentage of
inhibition was determined as follows: % inhibition=[1-(A/
B)]6100, where A is nontreated radioactivity (b-actin correction)
and B is treated radioactivity (b-actin correction).
RESULTS
Effects of various agents on expression of VEGF mRNA and
bFGF mRNA in human RCC cell lines
In the ﬁrst set of experiments, we investigated the effects of MPA,
IFN-a, IFN-g, minocycline and genistein on expression of VEGF
mRNA and bFGF mRNA. SMKT-R-1 and SMKT-R-3 cells were incu-
bated in either medium alone or in medium containing various
concentrations of agents for appropriate times. Based on previous
reports (Tamargo et al, 1991; Mukhopadhyay et al, 1995; Singh et
al 1995; Kim et al, 1996) and our preliminary results, we decided
the incubation times as follows: genistein for 12 h, MPA and mino-
cycline for 24 h, and IFN-a and IFN-g for 96 h. These incubation
periods as well as concentrations of agents did not affect the cell
proliferation (data not shown). We analysed the expression of VEGF
mRNA and bFGF mRNA by Northern blot analysis. MPA (10
75 M)
and IFN-a (100 IU ml
71) did not signiﬁcantly decrease the level of
either VEGF mRNA or bFGF mRNA in the cell lines. IFN-g
(100 IU ml
71) reduced the expression of VEGF mRNA and bFGF
mRNA in SMKT-R-1 cells by 30 and 32%, respectively. In SMKT-
R-3 cells, it reduced VEGF mRNA by 45%, but did not alter the
expression of bFGF mRNA. Minocycline (0.5 mgm l
71) also reduced
VEGF mRNA and bFGF mRNA in SMKT-R-1 cells by 45 and 22%,
respectively. It did not reduce either mRNA level in SMKT-R-3 cells
(Figure 1A and Table 1). Genistein signiﬁcantly inhibited the expres-
sion of VEGF mRNA in a dose-dependent manner. A high
concentration (100 mgm l
71) of genistein inhibited the expression
of VEGF mRNA by 55% in SMKT-R-1 and 30% in SMKT-R-3.
Genistein also induced 30–50% decreases in the level of bFGF
mRNA in both cell lines (Figure 2A,B).
Effect of genistein on expression of VEGF mRNA and
bFGF mRNA in human RCC cell lines treated with EGF
and hypoxia
Since genistein had a stronger inhibitory effect on expression of
VEGF mRNA and bFGF mRNA, we performed further experiments
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Figure 1 Effects of various agents on the expression of VEGF mRNA and bFGF mRNA in renal cell carcinoma cell lines (SMKT-R-1 and SMKT-R-3). Per
cent inhibition was determined by (17[nontreated radioactivity (b-actin correction)/treated radioactivity (b-actin correction)]6100).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 768–773using genistein in SMKT-R-3 cells. Several experiments have
demonstrated that expression of VEGF and bFGF is upregulated
by various factors, including cytokines and hypoxia (Tsai et al,
1995; White et al, 1995; Claffey and Robinson, 1996). Therefore,
we investigated whether EGF and hypoxia could induce VEGF
and bFGF expression in human RCC cell lines and whether genis-
tein could regulate the expression of these angiogenic factors under
stimulation of EGF and hypoxia. SMKT-R-3 cells were treated with
various concentrations of genistein (4, 40, 100 mgm l
71) in the
presence of EGF (100 ng ml
71) for 12 h. Under these conditions,
EGF increased the levels of VEGF mRNA and bFGF mRNA by
about only 1.4- and 1.2-fold respectively, compared with no treat-
ment (control). Genistein inhibited EGF-treated VEGF mRNA and
bFGF mRNA expression in a dose-dependent manner (Figure 3A).
SMKT-R-3 cells were cultured with various concentrations of
genistein (4, 40, 100 mgm l
71) under hypoxic conditions for
12 h. VEGF mRNA exhibited only a 1.4-fold increase in response
to hypoxia in this cell line. bFGF mRNA was not induced by
hypoxia. Expression of both VEGF mRNA and bFGF mRNA was
down-regulated by genistein (Figure 3B).
DISCUSSION
Angiogenesis occurs as a result of complex multi-step processes
such as activation of endothelium, destruction of basement
membrane by proteolytic enzymes, migration and proliferation of
endothelial cells, and formation of tubular structures (Folkman
and Shing, 1992). These steps are stimulated by the interactions
between tumour cells releasing angiogenic factors and their recep-
tors. Tumour angiogenesis can be inhibited by blocking more than
one of these steps. Prevention of tumour angiogenesis involves
inhibition of synthesis of angiogenic factors and blocking of their
receptors (Barillie et al, 1995; O’Brien and Harris, 1995). Until
now there have been few reports regarding the inhibition of expres-
sion and production of angiogenic factors (Sidky and Borden,
1987; Singh et al, 1995). Here we examined whether certain agents
could suppress the expression of VEGF mRNA and bFGF mRNA,
which are the main angiogenic factors in RCC (Takahashi et al,
1994).
Among the agents tested, genistein showed more prominent
suppression of the expression of VEGF mRNA and bFGF mRNA.
Genistein, an isoﬂavone in soybeans, was originally recognised as
a weak oestrogen and also an oestrogen antagonist at higher
concentrations (Zava and Deuw, 1994). Genistein inhibits the
tumour growth in various cancers in vitro and in vivo (Fotsis et
al, 1995). In addition, it is an inhibitor of angiogenesis (Fotsis et
al, 1995). Although the mechanism responsible for the inhibition
described above remains unclear, accumulating studies have shown
that genistein has multiple antitumour functions. Those include
inhibition of tyrosine kinase activity (Akiyama et al, 1987), topoi-
somerase II (Okura et al, 1988) and steroid metabolizing enzymes
such as 17b-hydroxysteroid oxidoreductase (Ma ¨kela ¨ et al, 1998), P-
450 aromatase (Adlercreutz et al, 1993) and 5-a reductase (Evans et
al, 1995), induction of differentiation (Record et al, 1997), G2/M
arrest, induction of p21
WAF1/CIP1 and apoptosis (Shao et al,
1998). With regard to angiogenesis, genistein blocks the expression
of VEGF induced by hypoxia by inhibiting src tyrosine kinase in
some cancer cell lines (Mukhopadhyay et al, 1995). Thus, we were
interested in whether genistein could suppress the expression of
VEGF and bFGF, which are the main angiogenic factors in RCC.
In our study, genistein down-regulated the expression of both
genes under all conditions examined, including EGF and hypoxic
treatments. Recently Shao et al (1998) reported that genistein
inhibited angiogenesis by decreasing vessel density and decreasing
the level of VEGF as well as transforming growth factor-b1i na
human breast cancer cell. Regarding bFGF, to our knowledge this
is the ﬁrst study to demonstrate that genistein also has a strong
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Table 1 Effects of various agents on expression of VEGF mRNA and bFGF mRNA in human RCC cell lines
Agents
MPA (M) IFN-a (IU ml
71) IFN-g (IU ml
71) Minocycline (mgm l
71)
Cells 10
77 10
76 10
75 10 100 10 100 0.5 5.0
SMKT-R1
VEGF mRNA +12
a 715 723 +14 +5 +22 730 746 735
bFGF mRNA +18 +10 +4 +22 +15 +11 732 723 +12
SMKT-R3
VEGF mRNA n.d.
b n.d. 714 n.d. 717 n.d. 749 +18 n.d.
bFGF mRNA n.d. n.d. +3 n.d. +5 n.d. +3 +22 n.d.
aPer cent inhibition was determined by (17[nontreated radioactivity (b-actin correction)/treated radioactivity (b-actin corection)]6100.
bn.d.=not determined.
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Figure 2 (A,B) The effect of genistein on the expression of VEGF
mRNA and bFGF mRNA in SMKT-R-1 and SMKT-R-3 cell lines. Both cell
lines were incubated for 12 h with serum-free medium containing 4, 40,
100 mgm l
71 of genistein.
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British Journal of Cancer (2002) 86(5), 768–773 ã 2002 Cancer Research UKinhibitory effect on expression of bFGF mRNA in RCC. This ﬁnd-
ing gives us important information about treatment for RCC,
because a recent report showed a signiﬁcant role of bFGF in regard
to development of metastasis (Slaton et al, 2001). Therefore, inhi-
bition of bFGF as well as VEGF by genistein may lead to
prevention of metastasis.
MPA is known to have an antiangiogenic effect via suppression
of plasminogen activator activity (Blei et al, 1993). In our study,
MPA did not induce a signiﬁcant decrease in the level of either
VEGF mRNA or bFGF mRNA in the concentrations employed.
This ﬁnding is consistent with the report of Kim et al (1996) show-
ing that VEGF mRNA expression is not altered by MPA or
oestradiol in an in vivo model of endometrial carcinoma.
Our previous study showed that minocycline inhibits in vitro inva-
sion and experimental metastasis of mouse renal adenocarcinoma by
inhibiting type IV collagen degradation (Masumori et al, 1994).
However, the mechanism of action remains unclear. Thus, we inves-
tigated the effect of minocycline on the expression of VEGF mRNA
and bFGF mRNA. Minocycline (0.5 mgm l
71) showed a moderate
inhibitory effect on VEGF mRNA and bFGF mRNA expression only
in SMKT-R-1 cells. This result indicated that this phenomenon might
possibly be speciﬁc for SMKT-R-1 cells.
IFNs are multifunctional cytokines that regulate immune
responses as well as antiviral and antitumour activities. IFNs are
also inhibitors of angiogenesis. IFN-a and IFN-b have been shown
to have anti-angiogenic activity by suppressing the expression and
production of bFGF in various human tumour cells, including
RCC (Singh et al, 1995; Dinney et al, 1998). These ﬁndings
prompted us to examine whether INFs could down-regulate the
expression of VEGF as well as bFGF. However, in our study,
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Figure 3 (A, B) The effect of genistein on the expression of VEGF mRNA and bFGF mRNA in SMKT-R-3 cells treated with EGF or hypoxia. These cells
were incubated with serum-free medium and with 0, 4, 40, 100 mgm l
71 of genistein with EGF (100 ng ml
71) or under hypoxic conditions for 12 h.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 768–773neither the expression of VEGF mRNA nor that of bFGF mRNA
was altered by IFN-a, even though we did experiments under the
same conditions (time for treatment and drug concentration) as
previous researchers did. The ﬁnding that IFN-a failed to reduce
expression of VEGF mRNA is consistent with that of a previous
report (Dinney et al, 1998). However, regarding bFGF, our result
was in disagreement with those of other reports (Singh et al,
1995; Dinney et al, 1998). One explanation may be the difference
of subunits of IFN-a, because we used IFN-a-2b instead of the
IFN-a-2a used in other experiments. Another reason could be
the difference of cell lines examined.
Several experiments have demonstrated that expression of VEGF
and bFGF is up-regulated by various factors, including cytokines
such as EGF, TGF-a, platelet-derived growth factors, and hypoxia
(Claffey and Robinson, 1996). Hypoxia, in particular, is a strong
inducer of up-regulation of the VEGF gene. It induces 1.1- to
28.9-fold VEGF mRNA expression in normal and tumour cells in
vitro (White et al, 1995; Claffey and Robinson, 1996). Hypoxia-
stimulated VEGF expression is due to increases in both transcrip-
tional activity and mRNA stabilisation (Ikeda et al, 1995; Levy et al,
1995, 1996). In our study, hypoxia did not induce signiﬁcant up-
regulation of VEGF mRNA in the cell lines examined. This may
have been due to differences of sensitivity to hypoxia. Some reports
have demonstrated that human tumour cells with high expression
of VEGF mRNA exhibit persistent mRNA stabilisation through
oncogenic activation of tyrosine kinase and Ras protein, and fail
to further stabilise VEGF mRNA in response to hypoxia (White
et al, 1995, 1997). Furthermore, they observed that the higher
the basal abundance of the VEGF mRNA that tumour cell lines
exhibited, the less responsive to hypoxia they were. Since the cell
lines that we used, SMKT-R-1 and R-3, express VEGF mRNA at
a level higher than the glioblastoma multiforma cell line U-
251MG, which is known to contain high levels of VEGF mRNA
(Takahashi et al, 1994), our results may be consistent with those
ﬁndings.
Considering the effect of genistein on growth inhibition in RCC
cell lines (unpublished data), it may be a novel therapeutic agent
for RCC patients. However, since inhibition of the expression of
VEGF and bFGF by genistein was incomplete, genistein alone
may be insufﬁcient for a large metastatic RCC. Therefore, genistein
may be effective for chemoprevention for patients who are at high
risk for RCC (i.e. von Hippel-Lindau disease patients), or preven-
tion of metastasis for post-surgery patients.
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